LiangYiHui Secures Over RMB 100 Million Series C Financing with HaoYue Capital as Exclusive Financial Advisor

On February 16, Liangyihui, an innovative digital health platform in the oncology field, announced the completion of its Series C financing round, exceeding RMB 100 million. This round of financingLed by Qiming Venture Partners, with participation from Detong Capital, existing shareholder Danlu Capital, the Wang Jiaquan Family Office, Yuanju Capital, and existing shareholder Juhe Capital., Haoyue Capital served as the exclusive financial advisor for this round of financing.

Liangyihui was founded in 2015 and has since accumulated the largest online community of oncology healthcare providers and patients. Currently, nearly 200,000 oncologists and 300,000 cancer patients are active on its platform. Liangyihui also collaborates closely with major oncology hospitals to assist in patient education and management. Over the past six years, the company has evolved from a content-driven model to one characterized by technological innovation and data-driven operations, becoming the preferred online platform for oncology professionals and patients. Liangyihui offers an innovative digital healthcare platform tailored to physicians, patients, hospitals, and pharmaceutical companies, precisely matching supply and demand throughout the oncology drug treatment process. This ensures that cancer patients receive comprehensive diagnosis and treatment and timely access to high-quality medications.

Since the outbreak of the pandemic, Liangyihui has leveraged its platform value by organizing thousands of free clinical consultations for patients, successfully benefiting tens of thousands of individuals. During this period, it connected oncologists with patients through its online platform. As a digital platform serving all stakeholders, Liangyihui has become a trusted partner for patients, healthcare providers, and pharmaceutical companies alike.

In the future, Liangyihui will leverage digital application scenarios in oncology pharmaceuticals to deeply address the medical and medication needs of cancer patients and physicians. By integrating its proprietary internet hospital, it aims to evolve into a technology- and data-driven innovative digital healthcare platform for oncology, serving pharmaceutical companies, doctors, hospitals, and patients, ultimately benefiting patient care.

Mr. Wang Jue, Founder of LiangyihuiCancer is currently the most significant disease threatening public health and represents the most dynamic and promising field for new drug development. For many years, Liangyihui has remained committed to building a specialized, vertical platform dedicated to oncology, bringing together professional stakeholders from all sectors. We are devoted to creating the most comprehensive learning and intellectual property (IP) platform for oncologists, providing patients with the most accessible medical services, and offering pharmaceutical companies the most complete marketing solutions. We are delighted to partner with forward-looking professional healthcare investors—Qiming Venture Partners and DT Capital—as well as our long-standing shareholders who have accompanied the company’s growth, including Legend Capital, Danlu Capital, and Juhe Capital, along with their partners Wang Jiaquan of Nanping and Yuanju Capital, in supporting Liangyihui’s continued creation of long-term value in the field of oncology.

Mr. Hu Xubo, Partner at Qiming Venture Partners“The oncology sector has consistently been a hotspot for medical innovation and a key focus of our investment portfolio. Meanwhile, the online migration and digitalization of doctor-patient services represent a long-term trend. Through years of accumulation, Liangyihui has grown into China’s leading digital platform for oncology-related doctor-patient services, with its professional content and in-depth services highly recognized by physicians, patients, and pharmaceutical companies. We are honored to partner with the Liangyihui team to support its efforts in accelerating digital transformation in this field, thereby delivering richer, more precise, and smarter services to users.”

Mr. Xu Qian, Partner at DT Capital PartnersHe stated that he had visited the company in 2016, and more than four years later, he was delighted to find that its business model had been validated, growing it into China’s largest digital healthcare platform specializing in oncology. This fully demonstrates the founder’s foresight and execution capabilities. Innovative oncology drugs represent the hottest segment within the innovative drug industry. As these drugs continue to be launched in China, there is an urgent market demand for digital healthcare platforms focused on oncology drugs, offering broad growth prospects. As an innovative digital healthcare platform, Liangyihui effectively addresses the pain point of information asymmetry in cancer treatment, providing significant benefits to doctors, patients, and pharmaceutical companies, thereby establishing a clear competitive advantage. He expressed great pleasure in collaborating with the company’s team and both new and existing investors to support the company’s rapid growth and better provide data-driven precision services to all stakeholders in the field of cancer treatment, including doctors, patients, and pharmaceutical enterprises.

Ms. Lu Qinchao, Founding and Managing Partner of Danlu Capitalstated, “We have known Wang Jue for a long time and are delighted to have witnessed the development of Liangyihui and its sustained performance growth along the way. Liangyihui also aligns with Danlu’s investment focus on companies with long-term growth potential. The company has remained deeply rooted in the oncology niche, continuously delivering value to oncologists, which has earned recognition from the market and customers while establishing high competitive barriers. The industry potential of digital marketing is evident, and we remain bullish on Liangyihui’s digital marketing model focused on the specialized medical field. Meanwhile, we believe that pharmaceutical companies will continue to increase their digital marketing investments in the post-pandemic era, conveying information to physicians in a more transparent and efficient manner.”

Mr. Ding Yameng, Founding Partner of Haoyue CapitalIt was stated that digital pharmaceutical marketing has already become a mature model abroad, and internet healthcare represents an irreversible global trend. After five to six years of consolidation, this golden track in China has finally ushered in an explosive growth phase, catalyzed by the pandemic. We are optimistic about generalist platforms that have established absolute leading advantages, and even more bullish about the niche leaders that have emerged as the survivors in each vertical sector after intense market consolidation. Liangyihui not only possesses formidable resource barriers across pharmaceutical companies, hospitals, and physicians, but we are also pleased to observe its gradual transformation into a technology- and data-driven entity, evolving into an innovative digital oncology healthcare service platform serving pharmaceutical companies, physicians, hospitals, and patients.

Qiming Venture Partners was established in 2006 and has successively set up offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston, and the San Francisco Bay Area. Currently, Qiming Venture Partners manages nine U.S. dollar funds and six RMB funds, with total assets under management exceeding USD 5.9 billion. Since its inception, the firm has focused on investing in outstanding early-stage and growth-stage companies in industries such as TMT and Healthcare.

DT Capital Partners is a leading professional private equity fund management firm in China, with assets under management nearing RMB 20 billion. In recent years, it has nurtured six listed companies and a cohort of early-stage enterprises with significant technological breakthroughs in the healthcare sector, including Chipscreen Biosciences, the first innovative drug company to list on the STAR Market. DT Capital Partners is also among the earliest investment institutions to establish strategic partnerships with multiple local governments and prominent industrial groups, providing comprehensive services and support to its portfolio companies.

Danlu Capital is a healthcare-focused investment fund specializing in innovative medical technologies. It was co-founded in early 2018 by Lu Qinchao, former Partner at Sequoia Capital China, and Su Zhenbo, former Managing Partner of Fenxiang Investment Management. Its core team members hail from renowned venture capital firms and possess extensive healthcare industry resources in both China and the United States. Danlu Capital continues to deepen its focus on the early-stage healthcare and wellness sector, systematically investing across multiple domains, including innovative medical technologies such as high-value consumables, in vitro diagnostic reagents, consumer healthcare, and digital health, as well as innovative drugs and novel healthcare services.

Haoyue Capital, founded in January 2014, is committed to serving as a bridge connecting China’s healthcare industry with capital. Its research and transaction coverage spans multiple subsectors, including biopharmaceuticals, innovative medical devices, in vitro diagnostics (IVD) and precision medicine, healthcare services, and smart healthcare. The Haoyue Capital team comprises senior investment bankers with extensive experience in China’s healthcare sector. By closely monitoring market dynamics and investment trends in healthcare over the long term, the firm releases weekly healthcare investment updates and thematic research reports, offering Haoyue’s perspectives on new policies and emerging frontiers.